214 related articles for article (PubMed ID: 38280023)
1. Systematic review of mortality and survival rates for APDS.
Hanson J; Bonnen PE
Clin Exp Med; 2024 Jan; 24(1):17. PubMed ID: 38280023
[TBL] [Abstract][Full Text] [Related]
2. The First Iranian Cohort of Pediatric Patients with Activated Phosphoinositide 3-Kinase-δ (PI3Kδ) Syndrome (APDS).
Fekrvand S; Delavari S; Chavoshzadeh Z; Sherkat R; Mahdaviani SA; Sadeghi Shabestari M; Azizi G; Arzanian MT; Shahin Shamsian B; Eskandarzadeh S; Eslami N; Rae W; Condino-Neto A; Mohammadi J; Abolhassani H; Yazdani R; Aghamohammadi A
Immunol Invest; 2022 Apr; 51(3):644-659. PubMed ID: 33401995
[TBL] [Abstract][Full Text] [Related]
3. Clinical, Immunological, and Genetic Features in Patients with Activated PI3Kδ Syndrome (APDS): a Systematic Review.
Jamee M; Moniri S; Zaki-Dizaji M; Olbrich P; Yazdani R; Jadidi-Niaragh F; Aghamahdi F; Abolhassani H; Condliffe AM; Aghamohammadi A; Azizi G
Clin Rev Allergy Immunol; 2020 Dec; 59(3):323-333. PubMed ID: 31111319
[TBL] [Abstract][Full Text] [Related]
4. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
Michalovich D; Nejentsev S
Front Immunol; 2018; 9():369. PubMed ID: 29535736
[TBL] [Abstract][Full Text] [Related]
5. Successful haploidentical hematopoietic stem cell transplantation for activated phosphoinositide 3-kinase δ syndrome: Case report and literature review.
Yang X; Xi R; Bai J; Pan Y
Medicine (Baltimore); 2023 Feb; 102(5):e32816. PubMed ID: 36749229
[TBL] [Abstract][Full Text] [Related]
6. Activated phosphoinositide 3-kinase δ syndrome: Update from the ESID Registry and comparison with other autoimmune-lymphoproliferative inborn errors of immunity.
Maccari ME; Wolkewitz M; Schwab C; Lorenzini T; Leiding JW; Aladjdi N; Abolhassani H; Abou-Chahla W; Aiuti A; Azarnoush S; Baris S; Barlogis V; Barzaghi F; Baumann U; Bloomfield M; Bohynikova N; Bodet D; Boutboul D; Bucciol G; Buckland MS; Burns SO; Cancrini C; Cathébras P; Cavazzana M; Cheminant M; Chinello M; Ciznar P; Coulter TI; D'Aveni M; Ekwall O; Eric Z; Eren E; Fasth A; Frange P; Fournier B; Garcia-Prat M; Gardembas M; Geier C; Ghosh S; Goda V; Hammarström L; Hauck F; Heeg M; Heropolitanska-Pliszka E; Hilfanova A; Jolles S; Karakoc-Aydiner E; Kindle GR; Kiykim A; Klemann C; Koletsi P; Koltan S; Kondratenko I; Körholz J; Krüger R; Jeziorski E; Levy R; Le Guenno G; Lefevre G; Lougaris V; Marzollo A; Mahlaoui N; Malphettes M; Meinhardt A; Merlin E; Meyts I; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neubert J; Neven B; Nieters A; Nove-Josserand R; Oksenhendler E; Ozen A; Olbrich P; Perlat A; Pac M; Schmid JP; Pacillo L; Parra-Martinez A; Paschenko O; Pellier I; Sefer AP; Plebani A; Plantaz D; Prader S; Raffray L; Ritterbusch H; Riviere JG; Rivalta B; Rusch S; Sakovich I; Savic S; Scheible R; Schleinitz N; Schuetz C; Schulz A; Sediva A; Semeraro M; Sharapova SO; Shcherbina A; Slatter MA; Sogkas G; Soler-Palacin P; Speckmann C; Stephan JL; Suarez F; Tommasini A; Trück J; Uhlmann A; van Aerde KJ; van Montfrans J; von Bernuth H; Warnatz K; Williams T; Worth AJJ; Ip W; Picard C; Catherinot E; Nademi Z; Grimbacher B; Forbes Satter LR; Kracker S; Chandra A; Condliffe AM; Ehl S;
J Allergy Clin Immunol; 2023 Oct; 152(4):984-996.e10. PubMed ID: 37390899
[TBL] [Abstract][Full Text] [Related]
7. Conformational disruption of PI3Kδ regulation by immunodeficiency mutations in
Dornan GL; Siempelkamp BD; Jenkins ML; Vadas O; Lucas CL; Burke JE
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):1982-1987. PubMed ID: 28167755
[TBL] [Abstract][Full Text] [Related]
8. Respiratory Manifestations of the Activated Phosphoinositide 3-Kinase Delta Syndrome.
Condliffe AM; Chandra A
Front Immunol; 2018; 9():338. PubMed ID: 29556229
[TBL] [Abstract][Full Text] [Related]
9. Enhanced AKT Phosphorylation of Circulating B Cells in Patients With Activated PI3Kδ Syndrome.
Asano T; Okada S; Tsumura M; Yeh TW; Mitsui-Sekinaka K; Tsujita Y; Ichinose Y; Shimada A; Hashimoto K; Wada T; Imai K; Ohara O; Morio T; Nonoyama S; Kobayashi M
Front Immunol; 2018; 9():568. PubMed ID: 29675019
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunologic phenotype associated with activated phosphoinositide 3-kinase δ syndrome 2: A cohort study.
Elkaim E; Neven B; Bruneau J; Mitsui-Sekinaka K; Stanislas A; Heurtier L; Lucas CL; Matthews H; Deau MC; Sharapova S; Curtis J; Reichenbach J; Glastre C; Parry DA; Arumugakani G; McDermott E; Kilic SS; Yamashita M; Moshous D; Lamrini H; Otremba B; Gennery A; Coulter T; Quinti I; Stephan JL; Lougaris V; Brodszki N; Barlogis V; Asano T; Galicier L; Boutboul D; Nonoyama S; Cant A; Imai K; Picard C; Nejentsev S; Molina TJ; Lenardo M; Savic S; Cavazzana M; Fischer A; Durandy A; Kracker S
J Allergy Clin Immunol; 2016 Jul; 138(1):210-218.e9. PubMed ID: 27221134
[TBL] [Abstract][Full Text] [Related]
11. Disease Evolution and Response to Rapamycin in Activated Phosphoinositide 3-Kinase δ Syndrome: The European Society for Immunodeficiencies-Activated Phosphoinositide 3-Kinase δ Syndrome Registry.
Maccari ME; Abolhassani H; Aghamohammadi A; Aiuti A; Aleinikova O; Bangs C; Baris S; Barzaghi F; Baxendale H; Buckland M; Burns SO; Cancrini C; Cant A; Cathébras P; Cavazzana M; Chandra A; Conti F; Coulter T; Devlin LA; Edgar JDM; Faust S; Fischer A; Garcia-Prat M; Hammarström L; Heeg M; Jolles S; Karakoc-Aydiner E; Kindle G; Kiykim A; Kumararatne D; Grimbacher B; Longhurst H; Mahlaoui N; Milota T; Moreira F; Moshous D; Mukhina A; Neth O; Neven B; Nieters A; Olbrich P; Ozen A; Pachlopnik Schmid J; Picard C; Prader S; Rae W; Reichenbach J; Rusch S; Savic S; Scarselli A; Scheible R; Sediva A; Sharapova SO; Shcherbina A; Slatter M; Soler-Palacin P; Stanislas A; Suarez F; Tucci F; Uhlmann A; van Montfrans J; Warnatz K; Williams AP; Wood P; Kracker S; Condliffe AM; Ehl S
Front Immunol; 2018; 9():543. PubMed ID: 29599784
[TBL] [Abstract][Full Text] [Related]
12. Clinical spectrum and features of activated phosphoinositide 3-kinase δ syndrome: A large patient cohort study.
Coulter TI; Chandra A; Bacon CM; Babar J; Curtis J; Screaton N; Goodlad JR; Farmer G; Steele CL; Leahy TR; Doffinger R; Baxendale H; Bernatoniene J; Edgar JD; Longhurst HJ; Ehl S; Speckmann C; Grimbacher B; Sediva A; Milota T; Faust SN; Williams AP; Hayman G; Kucuk ZY; Hague R; French P; Brooker R; Forsyth P; Herriot R; Cancrini C; Palma P; Ariganello P; Conlon N; Feighery C; Gavin PJ; Jones A; Imai K; Ibrahim MA; Markelj G; Abinun M; Rieux-Laucat F; Latour S; Pellier I; Fischer A; Touzot F; Casanova JL; Durandy A; Burns SO; Savic S; Kumararatne DS; Moshous D; Kracker S; Vanhaesebroeck B; Okkenhaug K; Picard C; Nejentsev S; Condliffe AM; Cant AJ
J Allergy Clin Immunol; 2017 Feb; 139(2):597-606.e4. PubMed ID: 27555459
[TBL] [Abstract][Full Text] [Related]
13. Activated PI3Kδ syndrome type 2: Two patients, a novel mutation, and review of the literature.
Olbrich P; Lorenz M; Cura Daball P; Lucena JM; Rensing-Ehl A; Sanchez B; Führer M; Camacho-Lovillo M; Melon M; Schwarz K; Neth O; Speckmann C
Pediatr Allergy Immunol; 2016 Sep; 27(6):640-4. PubMed ID: 27116393
[TBL] [Abstract][Full Text] [Related]
14. PIK3R1 Mutation Associated with Hyper IgM (APDS2 Syndrome): A Case Report and Review of the Literature.
Yazdani R; Hamidi Z; Babaha F; Azizi G; Fekrvand S; Abolhassani H; Aghamohammadi A
Endocr Metab Immune Disord Drug Targets; 2019; 19(7):941-958. PubMed ID: 30799802
[TBL] [Abstract][Full Text] [Related]
15. Immunodeficiency due to a novel variant in PIK3CD: a case report.
Shashaani N; Chavoshzadeh Z; Ghasemi L; Ghotbabadi SH; Shiari S; Sharafian S; Shiari R
Pediatr Rheumatol Online J; 2023 Jul; 21(1):71. PubMed ID: 37475052
[TBL] [Abstract][Full Text] [Related]
16. Disseminated and Congenital Toxoplasmosis in a Mother and Child With Activated PI3-Kinase δ Syndrome Type 2 (APDS2): Case Report and a Literature Review of Toxoplasma Infections in Primary Immunodeficiencies.
Karanovic D; Michelow IC; Hayward AR; DeRavin SS; Delmonte OM; Grigg ME; Dobbs AK; Niemela JE; Stoddard J; Alhinai Z; Rybak N; Hernandez N; Pittaluga S; Rosenzweig SD; Uzel G; Notarangelo LD
Front Immunol; 2019; 10():77. PubMed ID: 30891027
[TBL] [Abstract][Full Text] [Related]
17. Clinical practice guideline for activated phosphatidyl inositol 3-kinase-delta syndrome in Japan.
Moriya K; Mitsui-Sekinaka K; Sekinaka Y; Endo A; Kanegane H; Morio T; Imai K; Nonoyama S
Immunol Med; 2023 Dec; 46(4):153-157. PubMed ID: 37178059
[TBL] [Abstract][Full Text] [Related]
18. Disorders Related to PI3Kδ Hyperactivation: Characterizing the Clinical and Immunological Features of Activated PI3-Kinase Delta Syndromes.
Redenbaugh V; Coulter T
Front Pediatr; 2021; 9():702872. PubMed ID: 34422726
[TBL] [Abstract][Full Text] [Related]
19. Interim analysis: Open-label extension study of leniolisib for patients with APDS.
Rao VK; Kulm E; Šedivá A; Plebani A; Schuetz C; Shcherbina A; Dalm VA; Trizzino A; Zharankova Y; Webster S; Orpia A; Körholz J; Lougaris V; Rodina Y; Radford K; Bradt J; Relan A; Holland SM; Lenardo MJ; Uzel G
J Allergy Clin Immunol; 2024 Jan; 153(1):265-274.e9. PubMed ID: 37797893
[TBL] [Abstract][Full Text] [Related]
20. Phosphatase and tensin homolog (PTEN) mutation can cause activated phosphatidylinositol 3-kinase δ syndrome-like immunodeficiency.
Tsujita Y; Mitsui-Sekinaka K; Imai K; Yeh TW; Mitsuiki N; Asano T; Ohnishi H; Kato Z; Sekinaka Y; Zaha K; Kato T; Okano T; Takashima T; Kobayashi K; Kimura M; Kunitsu T; Maruo Y; Kanegane H; Takagi M; Yoshida K; Okuno Y; Muramatsu H; Shiraishi Y; Chiba K; Tanaka H; Miyano S; Kojima S; Ogawa S; Ohara O; Okada S; Kobayashi M; Morio T; Nonoyama S
J Allergy Clin Immunol; 2016 Dec; 138(6):1672-1680.e10. PubMed ID: 27426521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]